Lessons from the Viagra case
In 2004, the Chinese authorities invalidated Pfizer's patent on Viagra, unleashing sharp criticism about the country's record on IP protection. Samson G Yu and Ying Zhang of Kangxin Partners look behind the headlines to explain the decision and the lessons it offers patent applicants
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
